Search

Search Constraints

You searched for: Author/Creator Kaley, Thomas

Search Results

11. CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE. (12th November 2021)

12. CTNI-55. THE CDK4/6 INHIBITOR ABEMACICLIB IN PATIENTS WITH RECURRENT MENINGIOMA AND OTHER PRIMARY CNS TUMORS. (12th November 2021)

13. CTNI-64. FOCUSED ULTRASOUND MEDIATED BLOOD-BRAIN BARRIER PENETRANCE TO ENABLE CELL-FREE DNA (CFDNA) AS A LIQUID BIOPSY IN RECURRENT PRIMARY BRAIN TUMORS. (14th November 2022)

14. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. (4th February 2014)

15. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Issue 5 (3rd November 2015)

16. LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). (20th November 2020)

17. NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. (9th November 2020)

19. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Issue 1 (18th August 2018)